PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10450749-0 1999 Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). Etoposide 121-130 colony stimulating factor 2 Homo sapiens 0-48 11398878-6 2001 Maximal etoposide dose for the first cycle was 1920 mg/m2 for patients receiving GM-CSF and 1160 mg/m2 for patients receiving placebo (P = 0.045 one-sided), corresponding to a 65% higher etoposide dose and a 13% higher dose intensity with GM-CSF. Etoposide 8-17 colony stimulating factor 2 Homo sapiens 81-87 11398878-6 2001 Maximal etoposide dose for the first cycle was 1920 mg/m2 for patients receiving GM-CSF and 1160 mg/m2 for patients receiving placebo (P = 0.045 one-sided), corresponding to a 65% higher etoposide dose and a 13% higher dose intensity with GM-CSF. Etoposide 8-17 colony stimulating factor 2 Homo sapiens 239-245 11398878-6 2001 Maximal etoposide dose for the first cycle was 1920 mg/m2 for patients receiving GM-CSF and 1160 mg/m2 for patients receiving placebo (P = 0.045 one-sided), corresponding to a 65% higher etoposide dose and a 13% higher dose intensity with GM-CSF. Etoposide 187-196 colony stimulating factor 2 Homo sapiens 81-87 10450749-0 1999 Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). Etoposide 121-130 colony stimulating factor 2 Homo sapiens 50-56 9516141-6 1998 The role of p210(bcr-abl) in this delay is confirmed by comparing the effect of etoposide on the granulocyte-macrophage colony-stimulating factor (GM-CSF)-dependent UT7 cells and the bcr-abl-transfected GM-CSF-independent UT7/9 clone. Etoposide 80-89 colony stimulating factor 2 Homo sapiens 97-145 9726444-0 1998 A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer. Etoposide 42-51 colony stimulating factor 2 Homo sapiens 26-29 9516141-6 1998 The role of p210(bcr-abl) in this delay is confirmed by comparing the effect of etoposide on the granulocyte-macrophage colony-stimulating factor (GM-CSF)-dependent UT7 cells and the bcr-abl-transfected GM-CSF-independent UT7/9 clone. Etoposide 80-89 colony stimulating factor 2 Homo sapiens 147-153 9446257-4 1997 GM-CSF at the conventional dose of 5 micrograms/kg was utilized to increase the etoposide dose to 900 mg/m2 in a chemotherapy program including also carboplatin and ifosfamide in patients with small cell lung cancer. Etoposide 80-89 colony stimulating factor 2 Homo sapiens 0-6 8826608-1 1996 The purpose of this study was to evaluate the feasibility of chronic oral administration of etoposide with granulocyte-macrophage colony-stimulating factor (GM-CSF) [sargramostim (Immunex)] coadministration or premedication; to estimate and compare the frequency of toxicities accompanying etoposide administration alone, etoposide/GM-CSF coadministration and etoposide with GM-CSF premedication. Etoposide 92-101 colony stimulating factor 2 Homo sapiens 107-155 8826608-10 1996 GM-CSF coadministration (arm B) or premedication (arm C) with daily chronic oral etoposide was feasible and did not lead to excessive hematological toxicity. Etoposide 81-90 colony stimulating factor 2 Homo sapiens 0-6 8602629-0 1996 Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin. Etoposide 133-142 colony stimulating factor 2 Homo sapiens 39-87 8602629-1 1996 This is a double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of granulocyte-macrophage colony-stimulating-factor (GM-CSF) after dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP). Etoposide 195-204 colony stimulating factor 2 Homo sapiens 98-146 9020283-3 1997 The purpose of this phase I trial was to determine if granulocyte macrophage colony-stimulating factor (GM-CSF) support allows the dosage of the combination of etoposide and carboplatin to be increased above the previously determined MTD. Etoposide 160-169 colony stimulating factor 2 Homo sapiens 54-102 9020283-3 1997 The purpose of this phase I trial was to determine if granulocyte macrophage colony-stimulating factor (GM-CSF) support allows the dosage of the combination of etoposide and carboplatin to be increased above the previously determined MTD. Etoposide 160-169 colony stimulating factor 2 Homo sapiens 104-110 9020283-7 1997 With 5 microg/kg/d GM-CSF, the first etoposide and carboplatin cycle of 300 and 150 mg/m2/day x 3, respectively, could be administered with acceptable toxicity. Etoposide 37-46 colony stimulating factor 2 Homo sapiens 19-25 9020283-9 1997 These results demonstrate that GM-CSF alone has limited capability to support the repeated administration of high doses of etoposide and carboplatin. Etoposide 123-132 colony stimulating factor 2 Homo sapiens 31-37 9152970-12 1996 GM-CSF toxicity was the following, first dose reaction-one patient, local erythema-two patients, arthralgia-one patient, hypotension, chills, fever requiring GM-CSF discontinuation one patient RDI of cisplatin/etoposide was 0.77/0.62 in GM-CSF group, and 0.90/ 0.80 in patients who didn"t receive Leucomax. Etoposide 210-219 colony stimulating factor 2 Homo sapiens 0-6 8960144-6 1996 Mitoxantrone, cytarabine and etoposide given with GM-CSF gave a complete response rate and median survival similar to other combination treatments but there was no definite evidence that the duration of neutropenia was reduced by the addition of GM-CSF from the start of treatment. Etoposide 29-38 colony stimulating factor 2 Homo sapiens 50-56 8913281-0 1996 Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial. Etoposide 79-88 colony stimulating factor 2 Homo sapiens 0-48 8913281-0 1996 Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial. Etoposide 79-88 colony stimulating factor 2 Homo sapiens 50-56 8636749-0 1996 Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. Etoposide 0-9 colony stimulating factor 2 Homo sapiens 59-62 8636749-2 1996 We prospectively studied 20 children during initial remission of ALL and 16 children at relapse to assess CSF penetration of etoposide. Etoposide 125-134 colony stimulating factor 2 Homo sapiens 106-109 8636749-7 1996 The CSF etoposide concentration was > or = 10 nmol/L in 20 of 20, five of 10, and two of 11 courses following 300 mg/m2 i.v., 50 mg/m2 orally, and 25 mg/m2 orally, respectively, and was positively related to both the concurrent etoposide plasma concentration (R2 = .64) and to dose (R2 = .73). Etoposide 8-17 colony stimulating factor 2 Homo sapiens 4-7 8826608-1 1996 The purpose of this study was to evaluate the feasibility of chronic oral administration of etoposide with granulocyte-macrophage colony-stimulating factor (GM-CSF) [sargramostim (Immunex)] coadministration or premedication; to estimate and compare the frequency of toxicities accompanying etoposide administration alone, etoposide/GM-CSF coadministration and etoposide with GM-CSF premedication. Etoposide 92-101 colony stimulating factor 2 Homo sapiens 157-163 8826608-1 1996 The purpose of this study was to evaluate the feasibility of chronic oral administration of etoposide with granulocyte-macrophage colony-stimulating factor (GM-CSF) [sargramostim (Immunex)] coadministration or premedication; to estimate and compare the frequency of toxicities accompanying etoposide administration alone, etoposide/GM-CSF coadministration and etoposide with GM-CSF premedication. Etoposide 92-101 colony stimulating factor 2 Homo sapiens 332-338 8826608-1 1996 The purpose of this study was to evaluate the feasibility of chronic oral administration of etoposide with granulocyte-macrophage colony-stimulating factor (GM-CSF) [sargramostim (Immunex)] coadministration or premedication; to estimate and compare the frequency of toxicities accompanying etoposide administration alone, etoposide/GM-CSF coadministration and etoposide with GM-CSF premedication. Etoposide 92-101 colony stimulating factor 2 Homo sapiens 332-338 8826608-1 1996 The purpose of this study was to evaluate the feasibility of chronic oral administration of etoposide with granulocyte-macrophage colony-stimulating factor (GM-CSF) [sargramostim (Immunex)] coadministration or premedication; to estimate and compare the frequency of toxicities accompanying etoposide administration alone, etoposide/GM-CSF coadministration and etoposide with GM-CSF premedication. Etoposide 290-299 colony stimulating factor 2 Homo sapiens 157-163 8826608-1 1996 The purpose of this study was to evaluate the feasibility of chronic oral administration of etoposide with granulocyte-macrophage colony-stimulating factor (GM-CSF) [sargramostim (Immunex)] coadministration or premedication; to estimate and compare the frequency of toxicities accompanying etoposide administration alone, etoposide/GM-CSF coadministration and etoposide with GM-CSF premedication. Etoposide 290-299 colony stimulating factor 2 Homo sapiens 157-163 8826608-1 1996 The purpose of this study was to evaluate the feasibility of chronic oral administration of etoposide with granulocyte-macrophage colony-stimulating factor (GM-CSF) [sargramostim (Immunex)] coadministration or premedication; to estimate and compare the frequency of toxicities accompanying etoposide administration alone, etoposide/GM-CSF coadministration and etoposide with GM-CSF premedication. Etoposide 290-299 colony stimulating factor 2 Homo sapiens 157-163 8033046-0 1994 A phase I trial of intraperitoneal carboplatin and etoposide with granulocyte macrophage colony stimulating factor support in patients with intraabdominal malignancies. Etoposide 51-60 colony stimulating factor 2 Homo sapiens 66-114 7847254-0 1995 A phase II trial of intraperitoneal high-dose carboplatin and etoposide with granulocyte macrophage-colony stimulating factor support in patients with ovarian carcinoma. Etoposide 62-71 colony stimulating factor 2 Homo sapiens 77-125 7695978-0 1995 A comparison of two GM-CSF schedules to counteract the granulo-monocytopenia of carboplatin-etoposide chemotherapy. Etoposide 92-101 colony stimulating factor 2 Homo sapiens 20-26 7989942-1 1994 PURPOSE: This randomized, multicenter, dose-finding study was undertaken to determine the dose of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) that can safely reduce neutropenia after cyclophosphamide, doxorubicin, and etoposide (CAVP-16) chemotherapy in patients with small-cell lung cancer (SCLC). Etoposide 252-261 colony stimulating factor 2 Homo sapiens 116-164 8201386-1 1994 PURPOSE: A phase I trial was performed to evaluate the feasibility of escalating the dose of etoposide in dose-intensive ifosfamide, carboplatin, and etoposide (ICE) with granulocyte-macrophage colony-stimulating factor (GM-CSF). Etoposide 93-102 colony stimulating factor 2 Homo sapiens 171-219 8209278-3 1994 We have conducted a phase I study to determine the maximum tolerated dose of etoposide in the ifosfamide/carboplatin/etoposide (ICE) regimen when used with granulocyte-macrophage colony-stimulating factor (GM-CSF) support. Etoposide 77-86 colony stimulating factor 2 Homo sapiens 156-204 8209278-3 1994 We have conducted a phase I study to determine the maximum tolerated dose of etoposide in the ifosfamide/carboplatin/etoposide (ICE) regimen when used with granulocyte-macrophage colony-stimulating factor (GM-CSF) support. Etoposide 77-86 colony stimulating factor 2 Homo sapiens 206-212 8201386-1 1994 PURPOSE: A phase I trial was performed to evaluate the feasibility of escalating the dose of etoposide in dose-intensive ifosfamide, carboplatin, and etoposide (ICE) with granulocyte-macrophage colony-stimulating factor (GM-CSF). Etoposide 93-102 colony stimulating factor 2 Homo sapiens 221-227 8201386-1 1994 PURPOSE: A phase I trial was performed to evaluate the feasibility of escalating the dose of etoposide in dose-intensive ifosfamide, carboplatin, and etoposide (ICE) with granulocyte-macrophage colony-stimulating factor (GM-CSF). Etoposide 150-159 colony stimulating factor 2 Homo sapiens 171-219 8201386-17 1994 CONCLUSION: The addition of GM-CSF to a dose-intensive ICE regimen permitted dose escalation of etoposide to 900 mg/m2, with cumulative thrombocytopenia as the dose-limiting toxicity. Etoposide 96-105 colony stimulating factor 2 Homo sapiens 28-34 8445942-0 1993 Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. Etoposide 116-125 colony stimulating factor 2 Homo sapiens 0-48 8457473-0 1993 Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma. Etoposide 21-30 colony stimulating factor 2 Homo sapiens 44-50 19688296-10 2010 In all piglets, the mean fourth ventricular CSF peak etoposide level exceeded the mean peak lumbar etoposide levels by greater than 10-fold. Etoposide 53-62 colony stimulating factor 2 Homo sapiens 44-47 4039984-9 1985 CSF levels in two of these patients receiving high-dose etoposide were 1.28% and 2.09% of the serum concentrations. Etoposide 56-65 colony stimulating factor 2 Homo sapiens 0-3 1280674-0 1992 Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients. Etoposide 115-124 colony stimulating factor 2 Homo sapiens 0-48 1306884-2 1992 The profound myelotoxicity induced by cisplatin (40 mg/m2 daily x 5) and etoposide (150 mg/m2 daily x 3) provides a model to test the clinical value of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric cancer patients; myelosuppression occurred (absolute neutrophil count [ANC] < 500/microL) during 99 of 118 (84%) courses given to 44 children with refractory solid tumors. Etoposide 73-82 colony stimulating factor 2 Homo sapiens 170-218 16583432-1 2006 BACKGROUND: The purpose of the current study was to determine the toxicity and response of a fixed dose intracerebrospinal fluid (CSF) etoposide in the treatment of patients with newly diagnosed neoplastic meningitis (NM). Etoposide 135-144 colony stimulating factor 2 Homo sapiens 130-133 14984497-0 2004 Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial. Etoposide 87-96 colony stimulating factor 2 Homo sapiens 0-48 16110137-7 2005 CONCLUSIONS: Because of the increase in dose and dose-density afforded by the administration of GM-CSF, the relative dose intensity was increased by twofold for cyclophosphamide (400 vs 200 mg/m2/wk) and etoposide (120 vs 60 mg/m2/wk), and by 1.3-fold for doxorubicin (16.7 vs 12.5 mg/m2/wk). Etoposide 204-213 colony stimulating factor 2 Homo sapiens 96-102